NCT05160922 2026-03-30
Crizotinib Continuation Clinical Study
Pfizer
Phase 4 Active not recruiting
Clinical Trials
8 trialsNCT01979536 2024-04-30
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01606878 2024-01-05
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT01524926 2023-12-11
CREATE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02419287 2023-03-06
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
University of Milano Bicocca
Phase 2 Completed
NCT00585195 2023-02-08
PROFILE 1001
Pfizer
Phase 1 Completed
NCT00939770 2020-06-09
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
Phase 1/2 Completed
NCT02487316 2016-12-30
A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib
Peking University
Phase 4 Withdrawn